Interim Report, 1 January - 31 March 2010

Interim Report, 1 January - 31 March 2010

• Net sales were SEK 21.3 (17.5) m.
• The loss after tax was SEK -26.2 (-30.2) m.
• Earnings per share were SEK -1.25 (-1.45).
• Cash flow from operating activities was SEK -32.0 (-41.2) m.
• Cash and cash equivalents as of 31 March were SEK 184.1 (243.1) m.

Comments from the CEO
“The highlight for the first quarter was the launch of Xerclear™ in the home
markets of Sweden and Finland through our own sales and marketing organization.
This is a really exciting and important milestone for the company. An agreement
was also concluded with Meda AB who will launch Xerclear™ in North America and
the Xerese™ brand towards the end of this year and partnership discussions are
also well advanced for Europe and other geographies. The company also completed
an overhaul of its R&D portfolio and implemented a greatly improved portfolio
management system. This has resulted in us prioritizing 9 projects, 6 of which
are for infectious diseases. Medivir has also identified further infectious
disease projects, which can be fast tracked due to Medivir's expertise in this
segment. In order to exploit our portfolio to its full potential and to ensure
adequate resources for the commercial development of the company the Board of
Directors of Medivir has resolved to conduct a rights offering, subject to
approval by the Annual General Meeting” commented Ron Long Medivir's CEO.

For more information, please contact
Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292 or +46 (0)8 546
83123.